LNZTA3WT4 - Cell Line (ID:50028)

HMS LINCS ID: 50028
Name: LNZTA3WT4
Alternative Names: LNZTA3p53WT4; WT4
LINCS ID: LCL-1345
Alternative ID: CLO_0007371
Parent Cell Line:
Reference Source: ATCC CRL-11543
Organism: Homo sapiens
Organ: brain
Tissue:
Cell Type:
Details of Cell Type:
Donor Sex: unknown
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:3068, glioblastoma
Details of Disease:
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations: COSS1240170
Verification Reference Profile: DNA Profile (STR, source: ATCC): Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 9,12 D5S818: 12 D7S820: 10,12 THO1: 9.3 TPOX: 8,9 vWA: 15,17
Growth Properties: adherent
Recommended Culture Conditions: From MGH/CMT as specified by cell provider: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 1 microgram/ml tetracycline, 90%; heat-inactivated fetal bovine serum, 10%. Subculturing: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation ratio: A subcultivation ratio of 1:4 to 1:10 is recommended
Relevant Citations:
Usage Note:
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2016-04-04

Batch Information for HMSL50028-1:

HMS LINCS Batch ID: 50028-1
Provider: Center for Molecular Therapeutics (CMT; Massachusetts General Hospital)
Provider Catalog ID: MGH-344
Provider Batch ID:
Source Information: Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).
Date Received:
HMS QC Outcome:
Transient Modification(s):
Comments:
Date Publicly Available: 2012-04-25
Most Recent Update: 2015-06-29